Pancreatic cancer has been medicine's brick wall for decades. The FDA just cleared a drug that moved it, and the price arrived on the same day.
The drug is Rasonque, from Revolution Medicines. It is the first medicine the company has ever gotten approved.
What the trial showed
Patients on the drug lived a median of 13.2 months. Patients on chemotherapy alone lived 6.7 months.
It also cut the risk of death by 60% against the chemotherapy group. In cancer research, a six-month survival gain is considered enormous.
Context helps. About 67,000 Americans are diagnosed with pancreatic cancer each year, and about seven in eight die within five years. Many die within one.
Five-year survival at Stage 4 sits near 3%. Caught early it is closer to 40%, but early catches are rare.
When the results were shown at the largest gathering of cancer researchers in spring 2026, the room applauded for nearly a minute.
It is not a cure and it is not a first choice. The FDA cleared it for patients whose other treatments had already failed. Side effects include a harsh full-body rash and gastrointestinal trouble.
An Oklahoma City oncologist not involved in the studies described the approval as life-altering. Her point was that it finally changes the conversation a doctor gets to have.
Neil Williford, 75, of Cypress, Texas started the drug in July 2025 after chemotherapy failed on stage-4 disease that had reached his lungs. He was told at diagnosis he had less than a year, and has now lived more than two.
Now the sticker
Revolution Medicines set the list price at $39,800 a month. That is more than $477,000 a year.
Put it next to the rest of the industry and the range is the story.
| The price range in one industry | List cost |
|---|---|
| Rasonque, per month | $39,800 |
| Rasonque, per year | More than $477,000 |
| Merck cholesterol pill, 30-day supply | $315 |
| Hemlibra, average patient per year | About $600,000 |
| Regeneron gene therapy for infant deafness | Free in the U.S. |
Nothing about that spread comes from a formula. Companies price to what they believe the system will bear, and different managements reach very different answers.
Regeneron showed the other end in April 2026. Its gene therapy for children born deaf from a faulty gene affects 20 to 50 U.S. newborns a year, and the company said it will provide the drug free here.
Merck took a third path in July 2026 with a cholesterol pill at $10.50 a tablet, roughly $315 for a 30-day supply.
What an investor takes from it
The stock closed up nearly 2% on approval day. Most of the excitement had been paid for months earlier, when the shares jumped 41% in April 2026 on the trial result.
Merck had explored buying the company at a valuation near $30 billion. Those talks fell apart over price.
A commercial-intelligence firm estimates the drug could exceed $20 billion in yearly sales. That only happens if it also works in earlier disease and in other tumors, and the word "if" is carrying the entire number.
Big pharma needs somebody's science to work. Roughly $300 billion of annual drug sales will disappear to patent expirations by early next decade. Eli Lilly and Pfizer are chasing the same RAS biology.
That biology was called undruggable for years. RAS mutations drive as much as a third of all human cancers, and the protein was thought too flat for a drug to grip until a researcher found a pocket in 2013.
Detection may matter more than any of it. A Mayo Clinic model could let specialists spot pancreatic cancer on routine abdominal scans up to three years before it is usually found.
Pressure runs the other way too. Medicare negotiated lower prices on 15 high-selling medicines that take effect in 2027, shaving 38% to 85% off their list prices.
So the system that tolerates a $477,000 sticker is also clawing at prices from the other end. Both facts are real, and both belong in how you own this industry.